Carbon-Based Materials in Photodynamic and Photothermal Therapies Applied to Tumor Destruction

Within phototherapy, a grand challenge in clinical cancer treatments is to develop a simple, cost-effective, and biocompatible approach to treat this disease using ultra-low doses of light. Carbon-based materials (CBM), such as graphene oxide (GO), reduced GO (r-GO), graphene quantum dots (GQDs), and carbon dots (C-DOTs), are rapidly emerging as a new class of therapeutic materials against cancer. This review summarizes the progress made in recent years regarding the applications of CBM in photodynamic (PDT) and photothermal (PTT) therapies for tumor destruction. The current understanding of the performance of modified CBM, hybrids and composites, is also addressed. This approach seeks to achieve an enhanced antitumor action by improving and modulating the properties of CBM to treat various types of cancer. Metal oxides, organic molecules, biopolymers, therapeutic drugs, among others, have been combined with CBM to treat cancer by PDT, PTT, or synergistic therapies.

Carbon-Based Materials in Photodynamic and Photothermal Therapies Applied to Tumor Destruction

Within phototherapy, a grand challenge in clinical cancer treatments is to develop a simple, cost-effective, and biocompatible approach to treat this disease using ultra-low doses of light. Carbon-based materials (CBM), such as graphene oxide (GO), reduced GO (r-GO), graphene quantum dots (GQDs), and carbon dots (C-DOTs), are rapidly emerging as a new class of thera-peutic materials against cancer. This mini-review summarizes the progress in lasts years re-garding the applications of CBM in photodynamic (PDT) and photothermal (PTT) therapies for tumor destruction. The current understanding of the performance of modified CBM, hybrids and composites, is also addressed. This approach seeks to achieve an enhanced healing action by im-proving and modulating the properties of CBM to treat various types of cancer. Metal oxides, organic molecules, biopolymers, therapeutic drugs, among others, have been combined with CBM to treat cancer by PDT, PTT, or synergistic therapies.

Carbon-Based Materials in Photodynamic and Photothermal Therapies Applied to Tumor Destruction

Within phototherapy, a grand challenge in clinical cancer treatments is to develop a simple, cost-effective, and biocompatible approach to treat this disease using ultra-low doses of light. Carbon-based materials (CBM), such as graphene oxide (GO), reduced GO (r-GO), graphene quantum dots (GQDs), and carbon dots (C-DOTs), are rapidly emerging as a new class of thera-peutic materials against cancer. This mini-review summarizes the progress in lasts years re-garding the applications of CBM in photodynamic (PDT) and photothermal (PTT) therapies for tumor destruction. The current understanding of the performance of modified CBM, hybrids and composites, is also addressed. This approach seeks to achieve an enhanced healing action by im-proving and modulating the properties of CBM to treat various types of cancer. Metal oxides, organic molecules, biopolymers, therapeutic drugs, among others, have been combined with CBM to treat cancer by PDT, PTT, or synergistic therapies.

ELECTROCHEMICAL LYSIS IN ONCOLOGY: LITERATURE REVIEW

Recently, minimally invasive treatment modalities based on the application of various physical factors have been widely used in anticancer therapy. Electrochemical lysis is a method in which tumor cells are destroyed by local exposure to a constant low voltage electric current.Purpose: to present the current results of using electrochemical lysis in the treatment of various tumors, to describe the mechanism of tumor destruction and methods of delivering electric current to the tumor, as well as to evaluate the electrical parameters and positioning of the electrodes.Material and Methods.aliterature search included the Medical literatureanalysis and Retrieval system Online (Medline), the excerpta Medica data Base (embase), Web of science, scopus, Russian citation index. All articles were published before december 2019. The review included studies on the investigation electrochemical lysis in vitro, in vivo, as well as clinical observations and clinical studies in which electrochemical lysis has been used as an independent treatment, or in combination with other methods of anticancer treatment since 1984.Results. This review provides information regarding the electrochemical mechanisms of tumor destruction, anti-tumoral effects of electrochemical therapy, methodology for planning and distributing the dose of electrical lysis and positioning of electrodes. We have evaluated complications and oncological results. Electrochemical lysis is a safe, simple, effective, and relatively non-invasive method of antitumor treatment.Conclusion. The electrochemical lysis is a promising minimally invasive method which can be used for the treatment of tumors. However, long-term data are needed to validate this treatment before it can be included into clinical recommendation for the treatment of cancer patients.

Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells

Memory CD8+ T cells populate non-lymphoid tissues (NLTs) following pathogen infection, but little is known about the establishment of endogenous tumor-specific tissue-resident memory T cells (TRM) during cancer immunotherapy. Using a transplantable mouse model of prostate carcinoma, here we report that tumor challenge leads to expansion of naïve neoantigen-specific CD8+ T cells and formation of a small population of non-recirculating TRM in several NLTs. Primary tumor destruction by irreversible electroporation (IRE), followed by anti-CTLA-4 immune checkpoint inhibitor (ICI), promotes robust expansion of tumor-specific CD8+ T cells in blood, tumor, and NLTs. Parabiosis studies confirm that TRM establishment following dual therapy is associated with tumor remission in a subset of cases and protection from subsequent tumor challenge. Addition of anti-PD-1 following dual IRE + anti-CTLA-4 treatment blocks tumor growth in non-responsive cases. This work indicates that focal tumor destruction using IRE combined with ICI is a potent in situ tumor vaccination strategy that generates protective tumor-specific TRM.

Apoptotic body–mediated intercellular delivery for enhanced drug penetration and whole tumor destruction

Chemotherapeutic nanomedicines can exploit the neighboring effect to increase tumor penetration. However, the neighboring effect is limited, likely by the consumption of chemotherapeutic agents and resistance of internal hypoxic tumor cells. Here, we first propose and demonstrate that apoptotic bodies (ApoBDs) could carry the remaining drugs to neighboring tumor cells after apoptosis. To enhance the ApoBD-based neighboring effect, we fabricated disulfide-linked prodrug nanoparticles consisting of camptothecin (CPT) and hypoxia-activated prodrug PR104A. CPT kills external normoxic tumor cells to produce ApoBDs, while PR104A remains inactive. The remaining drugs could be effectively delivered into internal tumor cells via ApoBDs. Although CPT exhibits low toxicity to internal hypoxic tumor cells, PR104A could be activated to exert strong cytotoxicity, which further facilitates deep penetration of the remaining drugs. Such a synergic approach could overcome the limitations of the neighboring effect to penetrate deep into solid tumors for whole tumor destruction.

Understanding the mechanism of tumor regression

В статье подвергается сомнению существующее представление о природе рака. Предлагается другое объяснение природы этой болезни. Механизм рака атавистический. Он возник у докембрийских Metazoa, которые были сидячими и колониальными. У них он обеспечивал приспособление к сезонному ухудшению среды. Готовящиеся к диапаузе растущие почки этих животных стали эволюционными предшественниками злокачественной опухоли. Разрушения в организме, происходящие у этих Metazoa при подготовке к диапаузе, стали эволюционными предшественниками разрушений в организме, происходящих при раке. Рассасывания готовящихся к диапаузе почек у них стало эволюционным предшественником регрессии опухоли. Регрессия опухоли - явление редкое и для изучения поэтому трудное. Исследовать его следует не у высоко организованных животных и не у человека, а у колониальных асцидий. Поняв, как работает у них механизм рассасывания готовящихся к диапаузе почек, легче будет понять механизм регрессии опухоли. У растений готовящиеся к покою почки тоже иногда разрушаются. Исследование этого процесса у растений тоже может помочь пониманию механизма регрессии опухоли. The current understanding of the nature of cancer is being questioned, and another explanation of the nature of this disease has been proposed. The mechanism of cancer is atavistic. It emerged in the Precambrian Metazoa, which were sedentary and colonized. This mechanism provided them with a means to adapt to seasonal changes in the environment. The developing kidneys of these animals preparing for diapause were the evolutionary precursors of a malignant tumor. The destruction that occurred in their kidneys when preparing for diapause was the evolutionary predecessor of the tumor destruction in the human body that occurs during cancer regression. Resorption of diapause-preparing kidneys was an evolutionary precursor to tumor regression. Tumor regression is rare and therefore difficult to study. Thus, this phenomenon should not be investigated in highly organized animals or in humans, but in colonized ascidians. Having understood how the mechanism of resorption of their kidneys functions when preparing for diapause, it will be easier to understand the mechanism of tumor regression. In plants, buds preparing for dormancy are sometimes also destroyed. Studying this process can similarly help decipher the mechanism of tumor regression.

A Multiscale Immuno-Oncology on-Chip System (MIOCS) establishes that collective T cell behaviors govern tumor regression

T cell-based tumor immunotherapies such as CAR T cells or immune checkpoint inhibitors harness the cytotoxic potential of T cells to promote tumor regression. However, patient response to immunotherapy remains heterogeneous, highlighting the need to better understand the rules governing a successful T cell attack. Here, we develop a microfluidic-based method to track the outcome of T cell activity on many individual cancer spheroids simultaneously, with a high spatiotemporal resolution. By combining these parallel measurements of T cell behaviors and tumor fate with probabilistic modeling, we establish that the first recruited T cells initiate a positive feedback loop leading to an accelerated effector accumulation on the spheroid. We also provide evidence that cooperation between T cells on the spheroid during the killing phase facilitates tumor destruction. We propose that tumor destruction does not simply reflect the sum of individual T cell activities but relies instead on collective behaviors promoting both T cell accumulation and function. The possibility to track many replicates of immune-tumor interactions with such a level of detail should help delineate the mechanisms and efficacy of various immunotherapeutic strategies.